{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:05:43Z","timestamp":1790391943660,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["KY24038"],"award-info":[{"award-number":["KY24038"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.aohep.2025.102156","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:49:31Z","timestamp":1763628571000},"page":"102156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug-induced liver injury: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database (2004\u20132024)"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-5942","authenticated-orcid":false,"given":"Dongxuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2025.102156_bib0001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.14744\/hf.2024.2024.0003","article-title":"Drug-induced liver injury: diagnosis, management and the role of liver transplantation","volume":"6","author":"Ozturk","year":"2025","journal-title":"Hepatol Forum"},{"key":"10.1016\/j.aohep.2025.102156_bib0002","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/liv.15262","article-title":"Incidence and risk factors of drug-induced liver injury","volume":"42","author":"Li","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2025.102156_bib0003","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2025.102156_bib0004","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/ajg.2012.138","article-title":"A prospective nationwide study of drug-induced liver injury in Korea","volume":"107","author":"Suk","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2025.102156_bib0005","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2025.102156_bib0006","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2025.102156_bib0007","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.102156_bib0008","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG Clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2025.102156_bib0009","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12072-021-10144-3","article-title":"Drug-induced liver injury: asia Pacific Association of Study of Liver consensus guidelines","volume":"15","author":"Devarbhavi","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2025.102156_bib0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","article-title":"CSH guidelines for the diagnosis and treatment of drug-induced liver injury","volume":"11","author":"Yu","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2025.102156_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: a comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.aohep.2025.102156_bib0012","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00018-025-05744-3","article-title":"Tveden-Nyborg P. Mechanisms of drug induced liver injury","volume":"82","author":"Skat-Rordam","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.aohep.2025.102156_bib0013","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cld.2019.09.010","article-title":"Drug-induced liver injury resources and reporting for the clinician","volume":"24","author":"Isaacson","year":"2020","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.aohep.2025.102156_bib0014","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3350\/cmh.2019.1003","article-title":"Drug induced liver injury: east versus West - a systematic review and meta-analysis","volume":"26","author":"Low","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.aohep.2025.102156_bib0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/pds.3388","article-title":"Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data","volume":"22","author":"Shin","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.aohep.2025.102156_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16146","article-title":"Epidemiology and risk determinants of drug-induced liver injury: current knowledge and future research needs","volume":"45","author":"Suzuki","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2025.102156_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70002","article-title":"Drug-induced liver injury associated with emerging cancer therapies","volume":"45","author":"Chodup","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2025.102156_bib0018","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1111\/liv.16065","article-title":"Drug-induced liver injury related to gene therapy: a new challenge to be managed","volume":"44","author":"Larrey","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2025.102156_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/20420986221125006","article-title":"Pharmacovigilance: reporting requirements throughout a product's lifecycle","volume":"13","author":"Lucas","year":"2022","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.aohep.2025.102156_bib0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance - the next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.aohep.2025.102156_bib0021","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40264-013-0116-9","article-title":"Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database","volume":"36","author":"Brinker","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.aohep.2025.102156_bib0022","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/11535340-000000000-00000","article-title":"Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work","volume":"33","author":"Suzuki","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.aohep.2025.102156_bib0023","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/hepr.13883","article-title":"Analysis of drug-induced liver-related adverse event trend reporting between 1997 and 2019","volume":"53","author":"Kamimura","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.aohep.2025.102156_bib0024","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/clpt.2014.17","article-title":"Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics","volume":"95","author":"Fang","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.aohep.2025.102156_bib0025","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jamia\/ocv153","article-title":"OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data","volume":"23","author":"TA","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.aohep.2025.102156_bib0026","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.aohep.2025.102156_bib0027","article-title":"Contrastive analysis on the safety of brand and generic nebivolol: a real-world pharmacovigilance study based on the FDA adverse event reporting system","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.aohep.2025.102156_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"Bohm","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2025.102156_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2024.2430302","article-title":"Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database","author":"Li","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.aohep.2025.102156_bib0030","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.aohep.2025.102156_bib0031","article-title":"Oseltamivir-induced hepatotoxicity: a retrospective analysis of the FDA adverse event reporting system","volume":"20","author":"Yu","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2025.102156_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241244585","article-title":"Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis","volume":"15","author":"Jiang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.aohep.2025.102156_bib0033","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14740338.2023.2277801","article-title":"A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system","volume":"23","author":"Sun","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.aohep.2025.102156_bib0034","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","article-title":"Vorasidenib: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.aohep.2025.102156_bib0035","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.aohep.2025.102156_bib0036","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2025.102156_bib0037","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2025.102156_bib0038","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/ijms17020224","article-title":"Hepatotoxicity by drugs: the most common implicated agents","volume":"17","author":"Bjornsson","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.aohep.2025.102156_bib0039","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2016","journal-title":"Int J Mol Sci"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:53:16Z","timestamp":1780649596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125003813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1665268125003813"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102156","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced liver injury: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database (2004\u20132024)","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102156"}}